{"product_id":"alfasigma-five-forces-analysis","title":"Alfasigma Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlfasigma faces moderate supplier power, steady buyer leverage, and intense rivalry from multinational pharma players, while regulatory barriers lower new entrant risks but raise operational complexity; substitutes and technological disruption present selective threats to margins and growth.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Alfasigma’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of API Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPI supply is now concentrated: about 70–80% of small-molecule APIs are sourced from India and China, giving a handful of suppliers outsized influence. Alfasigma relies on these specialists for key gastroenterology and vascular APIs, including high-purity and on-patent intermediates. That supplier concentration raises risk: price hikes and lead-time delays have pushed API costs up 12–18% in 2023–24 for many European firms. Suppliers can thus demand premium pricing and tighter contractual terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers must meet strict Good Manufacturing Practice (GMP) rules from EMA and FDA, shrinking Alfasigma’s supplier pool—EU pharma GMP inspections in 2024 found 18% non-compliance, raising vetting costs.\u003c\/p\u003e\n\u003cp\u003eSwitching vendors triggers months-long re-certification and validation; a typical supplier qualification costs €0.5–1.5M and 6–12 months, so turnover is rare.\u003c\/p\u003e\n\u003cp\u003eThose compliant suppliers hold pricing leverage: concentrated supply plus high exit costs give them sustained bargaining power over Alfasigma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Input for Nutraceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Alfasigma expands in nutraceuticals, it needs high-grade organic compounds and natural extracts—markets where 2024 prices for botanical actives rose ~12% year‑on‑year due to crop shortfalls and certification costs. Seasonal variability and limited ethical suppliers concentrate supply: top 5 specialty herb extract vendors control an estimated 60% of EU imports. Scarcity lets suppliers charge premiums and set stricter contract terms, squeezing margins and raising input volatility risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Global Supply Chain Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOngoing geopolitical shifts and logistics disruptions through 2025 raised supplier importance for Alfasigma; 2024 global container rates spiked 35% y\/y, pushing preferred suppliers to charge premiums for reliability.\u003c\/p\u003e\n\u003cp\u003eSuppliers with diversified logistics networks can demand higher prices and guaranteed delivery windows; Alfasigma often accepts these terms to avoid stockouts of key generics and branded medicines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 container rate rise: +35% y\/y\u003c\/li\u003e\n\u003cli\u003ePreferred supplier premiums: estimated 5–12% on COGS\u003c\/li\u003e\n\u003cli\u003eStockout risk cost: up to €1.2M per major SKU week\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForward Integration Threats\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSome large API makers (eg, Cambrex, Lonza) moved downstream in 2024–25 by adding generic formulation or contract-manufacturing lines, boosting their revenue mix; Lonza reported 2024 pharma solutions growth of 7% yoy, signaling stronger downstream presence.\u003c\/p\u003e\n\u003cp\u003eThat forward integration raises supplier bargaining power: they can price inputs higher or compete in Alfasigma’s finished-goods space, risking margin squeeze and share loss.\u003c\/p\u003e\n\u003cp\u003eAlfasigma must tighten IP controls, diversify suppliers, and lock long-term contracts; a 3–5% procurement cost increase could cut EBITDA by ~1–2 percentage points on 2024 margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eForward integration by top API players (2024–25 growth signals)\u003c\/li\u003e\n\u003cli\u003eSuppliers become potential competitors — higher bargaining power\u003c\/li\u003e\n\u003cli\u003eActions: stronger IP, supplier diversification, long-term contracts\u003c\/li\u003e\n\u003cli\u003eImpact example: 3–5% input cost rise → ~1–2 pp EBITDA hit (2024 margins)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh supplier power: diversify sourcing, lock contracts, protect IP to curb rising API costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupplier power is high: 70–80% small-molecule APIs from India\/China, 2023–24 API cost rise 12–18%, GMP non-compliance 18% (2024), supplier qualification €0.5–1.5M and 6–12 months, container rates +35% y\/y (2024), preferred-supplier premiums 5–12% COGS, forward integration (Lonza +7% pharma solutions 2024) raises competitive risk; action: diversify, long-term contracts, tighten IP.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI sourcing concentration\u003c\/td\u003e\n\u003ctd\u003e70–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI cost rise\u003c\/td\u003e\n\u003ctd\u003e12–18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP non-compliance\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContainer rates\u003c\/td\u003e\n\u003ctd\u003e+35% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier premium\u003c\/td\u003e\n\u003ctd\u003e5–12% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Alfasigma that uncovers competitive drivers, supplier and buyer power, barrier-to-entry dynamics, substitutes, and emerging threats to its pharmaceutical market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet for Alfasigma—instantly visualize competitive pressure and regulatory risks to speed strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Providers and Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge hospital groups and pharmacy chains in Europe buy drugs in bulk; European hospital mergers cut supplier counts by ~20% since 2018, concentrating purchasing power. In 2024, the top 10 EU pharmacy chains accounted for roughly 35% of retail pharmacy sales, forcing firms like Alfasigma to accept discounts often 10–30% below list price. These buyers can switch to generics or competitors quickly, raising price pressure and margin risk for Alfasigma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental Pricing and Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn many of Alfasigma’s main markets, national health systems—covering over 60% of EU drug spend in 2023—act as ultimate payers and impose strict price controls, capping reimbursement levels. Governments use reference pricing and health technology assessments (HTAs) like Italy’s AIFA and NHS England’s NICE to set cost-effectiveness thresholds, limiting price increases. This centralized purchasing power compresses margins and forces Alfasigma to prioritize lower-cost formulations and real-world evidence to secure reimbursements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Sensitivity in the OTC and Nutraceutical Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpin the otc and nutraceutical segments individual consumers hold direct buying power show high price sensitivity global growth slowed to in while value-driven purchases rose europe per iqvia. with wellness skus online of switching brands after social media influence costs are low. alfasigma needs stepped-up branding marketing spend peers average revenue defend loyalty blunt end-user bargaining power.\u003e\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn the US, Pharmacy Benefit Managers (PBMs) control formulary access and often demand rebates; in 2024 PBM-negotiated rebates averaged ~33% off list price for branded drugs, letting PBMs push Alfasigma products off-preferred tiers and raise patient cost-sharing.\u003c\/p\u003e\n\u003cp\u003eThat gatekeeping lets PBMs extract steep price concessions and administrative fees, directly cutting Alfasigma’s net realized price and volume in insured markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePBM rebates ~33% (2024 industry average)\u003c\/li\u003e\n\u003cli\u003eFormulary exclusion reduces demand sharply\u003c\/li\u003e\n\u003cli\u003eHigher tiers increase patient out-of-pocket, lowering uptake\u003c\/li\u003e\n\u003cli\u003ePBMs can demand administrative fees and contracting concessions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Transparent Product Information\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe digital age gives physicians and patients instant access to clinical data and price comparisons, increasing transparency on efficacy and side effects and raising customer bargaining power against Alfasigma.\u003c\/p\u003e\n\u003cp\u003eInformation symmetry forces Alfasigma to justify its value proposition; in 2024 global pharma online search growth rose ~18% and 67% of patients report researching meds online, pressuring margins and pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatients researching meds: 67% (2024)\u003c\/li\u003e\n\u003cli\u003eOnline pharma search growth: ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eResult: higher price sensitivity, demand for clear efficacy data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers squeeze pharma: consolidation, PBMs \u0026amp; payers drive fierce price pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers exert strong pressure: EU hospital\/pharmacy consolidation cut supplier counts ~20% since 2018; top-10 EU pharmacy chains = ~35% retail sales (2024); PBM rebates ~33% (US, 2024); national payers cover \u0026gt;60% EU drug spend (2023) and use HTAs; OTC consumers price-sensitive (OTC growth 3.8% global, 2024). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-10 EU chains\u003c\/td\u003e\n\u003ctd\u003e~35% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital consolidation\u003c\/td\u003e\n\u003ctd\u003e-20% suppliers since 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM rebates\u003c\/td\u003e\n\u003ctd\u003e~33% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic payer share EU\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlfasigma Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Alfasigma Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written, fully formatted file you'll be able to download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final deliverable: ready for immediate use with comprehensive assessment of competitive rivalry, supplier and buyer power, threats of entry and substitution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747495653753,"sku":"alfasigma-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alfasigma-five-forces-analysis.png?v=1772199261","url":"https:\/\/matrixbcg.com\/products\/alfasigma-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}